• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by IO Biotech Inc.

    12/18/23 5:14:19 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IOBT alert in real time by email
    SC 13G 1 tm2333024d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. )*

     

    IO Biotech, Inc. 

     

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

     

    (Title of Class of Securities)

     

    449778 10 9

     

    (CUSIP Number)

     

    August 9, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

       ¨ Rule 13d-1(d)
       x Rule 13d-1(b)
       ¨ Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    CUSIP No.   449778 10 9
    1.

    Names of Reporting Persons

    Samsara BioCapital, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    3,640,015 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    3,640,015 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,640,015 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

           

    (1)This Schedule 13G is filed by Samsara BioCapital, L.P. (“Samsara LP”), Samsara BioCapital GP, LLC (“Samsara GP”) and Dr. Srinivas Akkaraju (“Akkaraju”) (and together with Samsara LP, Samsara GP, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.

     

    (3)This percentage is calculated based on 65,880,914 shares of Common Stock outstanding as of November 10, 2023, as reported in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed by the Issuer with the Securities and Exchange Commission (the “SEC”) on November 13, 2023.

     

    2 

     

     

    CUSIP No.   449778 10 9
    1.

    Names of Reporting Persons

    Samsara BioCapital GP, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)    (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    3,640,015 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    3,640,015 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,640,015 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.

     

    (3)This percentage is calculated based on 65,880,914 shares of Common Stock outstanding as of November 10, 2023, as reported in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed by the Issuer with the SEC on November 13, 2023.

     

    3 

     

     

     

    CUSIP No.   449778 10 9
    1.

    Names of Reporting Persons

    Dr. Srinivas Akkaraju

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)    (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    3,640,015 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    3,640,015 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    3,640,015 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

     

    (2)These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.

     

    (3)This percentage is calculated based on 65,880,914 shares of Common Stock outstanding as of November 10, 2023, as reported in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed by the Issuer with the SEC on November 13, 2023.

     

    4 

     

     

    Item 1.  
       
      (a) Name of Issuer
    IO Biotech, Inc.
      (b) Address of Issuer’s Principal Executive Offices
    Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark
    Item 2.  
       
      (a) Name of Person Filing
    Samsara BioCapital, L.P. (“Samsara LP”)
    Samsara BioCapital GP, LLC (“Samsara GP”)
    Srinivas Akkaraju (“Akkaraju”)
      (b) Address of Principal Business Office or, if none, Residence
    c/o Samsara BioCapital, LLC
    628 Middlefield Road
    Palo Alto, CA 94301
      (c) Citizenship
    Entities:

    Individuals:

     

    Samsara LP - Delaware
    Samsara GP - Delaware
    Akkaraju -      United States

      (d) Title of Class of Securities
    Common Stock, $0.001 par value (“Common Stock”)
      (e) CUSIP Number
    449778 10 9

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable
       
    Item 4. Ownership

     

    The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of December 18, 2023:

     

    Reporting
    Persons
     

    Shares Held

    Directly

      

    Sole

    Voting

    Power

      

    Shared

    Voting

    Power

      

    Sole

    Dispositive

    Power

      

    Shared

    Dispositive

    Power

      

    Beneficial

    Ownership

       Percentage of Class (2) 
    Samsara LP (1)   3,640,015    0    3,640,015    0    3,640,015    3,640,015    5.5%
    Samsara GP (1)   0    0    3,640,015    0    3,640,015    3,640,015    5.5%
    Akkaraju (1)   0    0    3,640,015    0    3,640,015    3,640,015    5.5%

     

      (1) These shares are held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is the managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.
      (2) This percentage is calculated based on 65,880,914 shares of Common Stock outstanding as of November 10, 2023, as reported in the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed by the Issuer with the SEC on November 13, 2023.

     

    5 

     

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    6 

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 18, 2023

     

    Samsara BioCapital, L.P.  
       
    By: Samsara BioCapital GP, LLC  
    its General Partner  
         
    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  
         
    Samsara BioCapital GP, LLC  
       
    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  
         
    /s/ Srinivas Akkaraju  
    Srinivas Akkaraju  

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    7 

     

     

    Exhibit(s):

     

    AJoint Filing Agreement

     

    8 

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of IO Biotech, Inc. is filed on behalf of each of us.

     

    Dated: December 18, 2023

     

    Samsara BioCapital, L.P.  
       
    By: Samsara BioCapital GP, LLC  
    its General Partner  
         
    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  
         
    Samsara BioCapital GP, LLC  
       
    By: /s/ Srinivas Akkaraju  
      Name: Srinivas Akkaraju  
      Title: Managing Member  
         
    /s/ Srinivas Akkaraju  
    Srinivas Akkaraju  

     

     

     

    Get the next $IOBT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IOBT

    DatePrice TargetRatingAnalyst
    11/30/2021$21.00Overweight
    Morgan Stanley
    11/30/2021Outperform
    Cowen & Co.
    11/30/2021$20.00Buy
    Jefferies
    More analyst ratings